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Introduction: Depressive symptoms are very common in patients with Parkinson’s dis-
ease (PD) and have a significant impact on the quality of life. Dopaminergic medication has
been shown to have an influence on the development of depressive symptoms.
Materials andmethods:The present study analyzed two groups of non-demented patients
with PD, with and without depressive symptoms, and reported the correlations between
antiparkinsonian medication [specifically levodopa (L-DOPA) and dopaminergic agonists]
with depressive symptoms.
Results: A strong statistically significant positive correlation between L-DOPA dosages
and the level of depressive symptoms has been revealed, suggesting that higher L-DOPA
dosages correlate with a worsening of depressive status. No significant correlation was
found with dopamine agonists.
Discussion:The results of this study show that in patients with PD, higher L-DOPA dosages
correlate with worse depressive symptoms. From this point of view, PD patients need to
be better diagnosed with respect to depressive symptoms and need additional treatment
adjustment when clinical manifestations of depression are present. Clinicians must be
aware that dopaminergic drugs are not sufficient to alleviate depressive symptoms.
Keywords: Parkinson’s disease, L-DOPA, depressive symptoms, dopamine agonists
INTRODUCTION
Parkinson’s disease (PD) is the second most frequent chronic neu-
rodegenerative disorder, affecting up to 2% among persons older
than 65 years of age (1) and nearly 10% of people older than
80 years (2). The non-motor symptoms in PD such as depression
and cognitive impairment are highly prevalent and have more
impact on the quality of life and health status than motor symp-
toms (3–5). Depression is one of the most common of these
non-motor symptoms. Up to 40% of PD patients suffer from
depression at the beginning of the disease [stage I on Hoehn and
Yahr scale (6)] and at the stage IV, the advanced stage of the disease,
up to 70% of patients will have suffered from it at some point of
their illness (7–10). Additionally, depression has been considered
as the single strongest predictor of quality of life in PD, even after
accounting for motor functioning (11, 12).
However, depression is often under-diagnosed in PD patients
(13, 14), with only 25% of patients who will actually receive
effective antidepressant treatment (15, 16). This could be due
to phenomenological differences between depression in PD and
depression as a primary affective disorder, as it has been sug-
gested previously (17–19). Additionally, the somatic symptoms
of depression (loss of appetite, sleep disturbances, motor retarda-
tion, fatigue, loss of energy or the rarefaction of facial expressions)
are very often observed in PD patients without depression and this
creates an overlap between depression and Parkinsonism (20).
Previous studies brought to evidence a relationship between
PD medication therapies, depressive symptoms, and cognition.
Levodopa (l-DOPA) and dopaminergic agonists have been shown
to reduce the depressive symptoms (21, 22), to have no effects
(23, 24), or to worsen the depression in PD patients (25–28).
Further, a direct correlation between depression and cognitive per-
formance in PD patients has been emphasized (29–32) specifically
with memory and executive functions (30, 33). Each episode of
severe major depression in non-PD elderly people was shown to
increase the risk of dementia by 14% (34) and if mild cognitive
impairment was accompanied by depression, the risk of devel-
oping dementia was multiplied by two (35). This outlined the
idea that depression may be a risk factor or a precursor symp-
tom of dementia (35). Nevertheless, other studies reported no
relationship between depression and cognition in PD patients
(36–38), which raises the question whether medication impacts
depression’s development in PD.
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On the other hand, depressive symptoms have been associated
with dopamine dysregulation syndrome (DDS) (39), which is an
addiction-like state marked by excessive dopaminergic medica-
tion usage, particularly l-DOPA (40). PD patients with DDS have
been shown to exhibit enhanced l-DOPA induced ventral striatum
dopamine release compared with non-DDS patients, which led to
the conclusion that sensitization of ventral striatal circuitry is asso-
ciated with compulsive medication use (41). This is in line with
the l-DOPA overdose in the ventral striatum due to differential
dopaminergic depletion in PD (42,43),which determines a dysreg-
ulation of ventral striatum functions. Nevertheless, a cumulative
prevalence rate of DDS was not reported (40), but considering
that the most common impulse control disorder present in PD, the
pathological gambling, was found in 8% of patients on l-DOPA
(44), the rate of DDS is probably lower.
The aim of this study was to determine the interrelation
between depressive symptoms and medication, and their influence
on cognition. Based on previous studies (25–28), we hypothesized
that l-DOPA will have a negative impact on depressive symptoms.
For this purpose, the present study explored: (a) the comparison
between PD patients with depressive symptoms and those without
depressive symptoms, and (b) the correlation between dopamin-
ergic medication (l-DOPA and agonists), depressive symptoms,
and cognition.
MATERIALS AND METHODS
SUBJECTS
Forty non-demented PD patients were included in this study. They
were right and left handed, at stages I and II of the Hoehn and Yahr
scale (6). All patients were recruited from the Movement Disor-
ders Unit of the McGill University Health Center, and the Unité
des Troubles du Mouvement André Barbeau, in Montreal. Patients
were diagnosed by movement disorders neurologists and met the
United Kingdom Brain Bank criteria for the diagnosis of idio-
pathic PD (45). Clinical characteristics, including medication, are
presented in Table 1. All PD patients were receiving dopamin-
ergic medication and were responsive to it. Patients with other
comorbidities (e.g., stroke, Alzheimer’s disease), with history of
significant brain trauma or with severe psychiatric disturbance
(e.g., schizophrenia, bipolar disorder) were excluded from the
study. None of the patients were taking specific antidepressant
medication at the time of the study or at least 3 months prior to it.
All neuropsychological procedures were conducted in accordance
with the Declaration of Helsinki. All participants provided written
informed consent and the protocol was approved by the Research
Ethics Committee of the Regroupement Neuroimagerie Québec.
EVALUATION
Each PD patient underwent an evaluation of the severity of the
disease using the Unified Parkinson’s Disease Rating Scale Part III
(UPDRS), an assessment of the cognitive status using the Montreal
Cognitive Assessment scale (MoCA) (46), and a comprehensive
neuropsychological evaluation battery, performed by a licensed
neuropsychologist (Dr. MCB). During the neuropsychological
evaluation, the assessment of the UPDRS and the MoCA scales,
all PD patients were off-medication, and did not receive any drugs
related to PD for at least 12 h prior to the evaluation. A second
Table 1 | Demographic data for patients with Parkinson’s disease (PD).
PD-non-
depressed
PD-depressed P
Number (female/male) 20 (9/11) 20 (5/15) p=0.19c
Age (years)a 60.225±5.64 63.05±5 p=0.087
Education (years)a 14.05±3.25 14.25±3.04 p=0.74
L-DOPA dosage (mg)a 282.5±232.99 535±317.93 p=0.027b
Agonists dosage (mg)a 1.69±1.46 2.15±2.7 p=0.092
UPDRS off totala 26.42±8.12 30.45±8.65 p=0.079
UPDRS off tremora 0.48±0.40 0.53±0.36 p=0.058
UPDRS off rigiditya 1.02±0.43 1.27±0.45 p=0.09
MoCA ona 28.06±1.6 26.76±1.72 p=0.031b
MoCA offa 28.05±1.23 26.53±2.19 p=0.035b
BDI totala 4.7±2.33 14.6±6.62 p=0.0001b
BDI cognitiona 0.64±0.72 2.13±1.36 p=0.002b
BDI somatica 2.89±1.53 4.71±2.11 p=0.002b
BDI mooda 1.28±1.32 5.94±3.9 p=0.001b
RAVLT-Trial 15a 0.24±0.96 −0.97±1.28 p=0.054
RAVLT-Trial 6a 0.35±0.79 −0.75±1.35 p=0.061
RAVLT-Trial 7a 0.43±0.93 −0.62±1 p=0.021b
RAVLT-Recognition list Aa −0.03±1.15 −1.87±2.48 p=0.031b
Brixtona 5.35±2.03 5.15±2.21 p=0.81
Medication, no.of patients
L-DOPA/DDCI 15 18
Agonist 12 17
MAO-B inhibitor 9 9
COMT Inhibitor 6 9
PD-depressed, patients with Parkinson’s disease and with depressive symptoms;
PD-non-depressed, patients with Parkinson’s disease and without depressive
symptoms; L-DOPA, levodopa based medication; agonist, dopaminergic agonist
medication; UPDRS off total/tremor/rigidity, United Parkinson’s Disease Rating
Scale Part III, off-medication for the total scores, the rigidity corresponding
scores and the tremor corresponding scores; MoCA on/off, Montreal Cognitive
Assessment Scale, on-/off-medication; BDI, Beck Depression Inventory; cogni-
tion/somatic/mood/affect, the cognition/somatic/mood/affect sub-groups of the
BDI scale; RAVLT, Rey Auditory Verbal Learning Test; Brixton, Brixton test; DDCI,
DOPA decarboxylase inhibitor; MAO-B, monoamine oxidase isoform B; COMT,
cathechol-O-methyltransferase.
aMean scores±SD are presented.
bThis value indicates a significant difference between groups.
cDifference was assessed using the χ2-test.
evaluation using the MoCA scale on-medication was performed
after 1 week. The neuropsychological assessment was based on the
five relevant cognitive domains suggested by the Movement Dis-
orders Society Task-Force for level II comprehensive assessment
(47): attention and working memory; executive function; lan-
guage; memory; visuospatial functions (Table 2). We chose the
off-medication period due to several reasons: (A) previous studies
reported that dopamine loss in the ventral striatum is less severe
than in the putamen and dorsal striatum (48), and depression has
been associated with functional activity in the ventral striatum
(49, 50); (B) it has been suggested that l-DOPA doses necessary
to restore the dopamine loss in the dorsal striatum may over-
dose the less severely depleted areas, i.e., the ventral striatum (51)
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Table 2 | Neuropsychological test battery according to cognitive
domain.
Cognitive
domain
Test
Attention and
working memory
Trail Making Test Part A (53)
Digit span test (54)
Stroop color-word test, reading and color naming
parts (55)
Tower of London (56)
Brixton (57)
Executive function MEC, orthographic verbal fluency subtest (58)
Trail Making Test Part B (53)
Stroop color-word test, interference part (55)
Wechsler Abbreviated Scale of Intelligence,
vocabulary subtest (59)
Language Boston Naming (60)
MEC, semantic verbal fluency subtest (58)
Rey Auditory Verbal Learning Test (61)
Memory Wechsler Memory Scale third edition, logical
memory subtest (immediate and delayed
recalls) (54)
Hooper Visual Organization Test (62)
Visuospatial function Clock-drawing subtest of the MoCA, evaluated by
scores of Schulman et al.(46, 63, 64)
MEC, Montreal evaluation of communication protocol
MoCA, Montreal Cognitive Assessment Scale.
thereby having the potential of inducing the depressive symptoms
due to this overdose; (C) l-DOPA medication withdrawal has a
detrimental effect on the cognitive loop between the dorsolateral
prefrontal cortex and the dorsal caudate nucleus, specifically with
task-set switching (51), thus we argue that l-DOPA treatment
enhances the cognitive capacities in PD patients in this specific
loop. From this point of view, studying the patients in an off-
medication period, allowed us to analyze the real off-medication
level of cognitive impairment, to quantify it, and to correlate it
with depression symptoms.
The depressive status was evaluated using the Beck Depres-
sion Inventory II scale (BDI-II) (52) when patients were off-
medication. Because the complete BDI-II evaluation is not suf-
ficient to apply a clear diagnosis of depression, as this cannot
substitute a formal clinical evaluation, we considered the intensity
of depressive symptoms as an evaluation factor.
The median BDI-II score, which was 9.8, was considered
the distinguishing level for creating two groups – PD-depressed
(patients with a score higher than the median BDI-II and which
were considered to have significant depressive symptoms) and
PD-non-depressed (patients with a lower score and without sig-
nificant depressive symptoms). Thus, the results of this study
refer to the intensity of depressive symptoms as computed using
the BDI-II scale. In order to reveal the presence of any correla-
tion trends, we also analyzed the results for all PD patients as a
group (PD-All).
Medications were grouped depending on their action. Thus,
the “l-DOPA” group included the drugs that use the dopamine
precursor (l-DOPA) and a DOPA decarboxylase inhibitor (such as
carbidopa or benserazide) and the group of“Agonists”included the
medication that activates the dopamine receptors in the absence
of dopamine (ropinirole and pramipexole).
STATISTICAL ANALYSIS
The overall analysis was performed using the statistical software
package SPSS 17 (SPSS, Chicago, IL, USA). We divided the BDI-II
scale in three components: the cognitive component (comprising
the items: 12. loss of interest; 13. indecisiveness; 19. concentra-
tion difficulty), the physical or “somatic” component (based on
the items: 15. loss of energy; 16. changes in sleeping pattern; 18.
changes in appetite; 20. tiredness; 21. loss of interest in sex), and the
affective or “mood” component (comprising the items: 1. sadness;
2. pessimism; 3. past failure; 4. loss of pleasure; 5. guilty feelings; 6.
punishment feelings; 7. self-dislike; 8. self-criticalness; 9. suicidal
thoughts or wishes; 10. crying; 11. agitation; 14. worthlessness;
17. irritability) (65, 66). This was performed in order to analyze
the significance of each component and to assess which aspects
of this scale are more sensitive to antiparkinsonian therapy. Addi-
tionally, the UPDRS scale was divided into two sub-groups: the
tremor sub-group, which included the five tremor related scores
of the UPDRS, and the rigidity sub-group, which included the
five questions related to rigidity. Analyses were performed ini-
tially for all PD patients and afterward in a separate manner for
two groups: the PD-depressed and the PD-non-depressed groups.
The distribution of variables of the PD groups showed a nor-
mal distribution and no outliers were found. To compare the
groups on the continuous variables, an ANOVA analysis and a
Pearson product–moment correlation coefficient analysis was per-
formed. The included continuous variables were: age; daily dosage
of l-DOPA; daily dosage of agonist medication; MoCA scores
on-medication; MoCA scores off-medication; neuropsychologi-
cal scores; components of the BDI-II scale (cognition, somatic,
mood); sub-groups of the motor part of the UPDRS scale (tremor
and rigidity). Categorical variables were assessed using the χ2-
test. Statistical threshold was set to p< 0.05. Due to the fact that
BDI components and RAVLT neuropsychological tests revealed
significant results, an additional post hoc Bonferroni correction
(67) was performed for the BDI results (which included BDI
total, BDI cognition, BDI somatic, and BDI mood) and for the
RAVLT results (which included RAVLT-Trial 15, RAVLT-Trial 6,
RAVLT-Trial 7, and RAVLT-Recognition list A), which lowered the
statistical significance to p< 0.0125. Bivariate analyses were per-
formed in order to validate the correlation results and no outliers
were identified.
RESULTS
ANOVA RESULTS
The two PD groups did not differ in age, education, or evolu-
tion of disease (as measured by the UPDRS scale). Neverthe-
less, a statistically significant difference was determined between
the PD-depressed and PD-non-depressed groups with respect
to the daily dosage of l-DOPA (p= 0.027). Strikingly, the PD-
depressed patients received higher dosages of l-DOPA (Table 1).
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Table 3 | Correlation results between the groups.
Duration
of disease
UPDRS off
total
UPDRS off
rigidity
BDI
cognition
BDI
somatic
RAVLT-
recognition
RAVLT
15
RAVLT 6 RAVLT 7 Brixton
PD-All L-DOPA r =0.423;
p=0.006a
r =0.461;
p=0.003a
r =0.491;
p=0.001a
r =0.417;
p=0.018a
r =0.353;
p=0.044a
r =−0.542;
p=0.001b
r =−0.384;
p=0.014b
r =−0.383;
p=0.015b
r =−0.408;
p=0.009b
r =−0.05;
p=0.341
Agonists r =0.392;
p=0.035a
r =−0.019;
p=0.924
r =−0.01;
p=0.958
r =−0.033;
p=0.883
r =−0.035;
p=0.87
r =0.118;
p=0.542
r =0.037;
p=0.849
r =0.102;
p=0.597
r =0.043;
p=0.823
r =0.047;
p=0.809
PD-non-
depressed
L-DOPA r =0.607;
p=0.005a
r =0.403;
p=0.078
r =0.446;
p=0.049a
r =0.445;
p=0.074
r =0.38;
p=0.132
r =−0.394;
p=0.086
r =−0.118;
p=0.619
r =−0.028;
p=0.908
r =−0.14;
p=0.555
r =0.425;
p=0.062
Agonists r =0.588;
p=0.044a
r =−0.151;
p=0.639
r =−0.028;
p=0.93
r =0.302;
p=0.397
r =0.138;
p=0.703
r =−0.181;
p=0.174
r =0.227;
p=0.478
r =0.235;
p=0.461
r =0.25;
p=0.434
r =−0.121;
p=0.707
PD-
depressed
L-DOPA r =0.189;
p=0.426
r =0.418;
p=0.067
r =0.425;
p=0.062
r =0.218;
p=0.649
r =0.485;
p=0.057
r =−0.465;
p=0.039b
r =−0.288;
p=0.218
r =−0.329;
p=0.156
r =−0.34;
p=0.142
r =−0.537;
p=0.015b
Agonists r =0.307;
p=0.23
r =0.054;
p=0.836
r =0.013;
p=0.961
r =−0.344;
p=0.249
r =−0.275;
p=0.342
r =0.293;
p=0.253
r =−0.14;
p=0.957
r =0.104;
p=0.69
r =−0.026;
p=0.923
r =0.161;
p=0.537
PD-non-depressed, patients with Parkinson’s disease and without depressive symptoms; PD-depressed, patients with Parkinson’s disease and with depressive symp-
toms; L-DOPA, levodopa-based medication; Agonists, dopaminergic agonist medication; UPDRS off, United Parkinson’s Disease Rating Scale, off-medication; UPDRS
off rigidity, the rigidity sub-group of the UPDRS scale, which included the five questions related to rigidity; BDI, Beck Depression Inventory; cognition/somatic, the cog-
nition/somatic sub-groups of the BDI scale; RAVLT, Rey Auditory Verbal LearningTest; Brixton, Brixton test. If r=±0.7 or higher, there is a very strong positive/negative
relationship; if r=±0.4 to ±0.69, there is a strong positive/negative relationship; if r=±0.3 to ±0.39, there is a moderate positive/negative relationship.
aThis value indicates a positive correlation.
bThis value indicates a negative correlation.
Additionally, these two groups were different with respect to
MoCA cognitive performance on and off-medication (p= 0.03)
as well as the neuropsychological scores of RAVLT-Trial 7, delayed
recall (p= 0.021), and RAVLT-recognition list A, recognition test
(p= 0.031), with the PD-depressed group always having the
worse performance. It should be noted that these differences
did not remain significant after applying the post hoc Bonferroni
correction.
CORRELATIONS IN ALL PD PATIENTS
The analysis for the group of all PD patients revealed a strong
positive correlation between medication dosage (l-DOPA and
agonists) and duration of disease, indicating that the more the
duration of the disease, the higher the dosages of l-DOPA and
agonists (Table 3). Furthermore, only l-DOPA dosage showed a
positive correlation with the total UPDRS score, with the rigid-
ity sub-group score of the UPDRS scale and with cognition and
somatic components of the BDI-II scale. These correlations indi-
cated that with higher UPDRS total score and higher UPDRS
rigidity score, higher doses of l-DOPA were used. Importantly,
a higher dosage of l-DOPA was associated with higher scores for
depressive symptoms, specifically the cognition and somatic com-
ponents of the BDI-II scale (to note that higher BDI scores mean
worse clinical presentation of the BDI-II components of “cogni-
tion”and“somatic”). Additionally, only l-DOPA revealed negative
correlation with all RAVLT scores (recognition, trial 15, trial 6, and
trial 7), indicating that an increased dosage of l-DOPA might have
the potential of inducing worse performance on cognitive tests like
verbal learning and memory, retention of information, encoding
and retrieval of information, and subjective organization. On the
other hand, dopaminergic agonists showed no other correlations.
CORRELATIONS IN DEPRESSED AND NON-DEPRESSED PD PATIENTS
The PD-non-depressed patients revealed strong positive corre-
lations between medication dosage (l-DOPA and agonists) and
duration of disease. This result was also revealed in the PD-All
group, which suggests that PD-non-depressed patients where dri-
ving the positive correlation for PD-All. On the other hand,
no such correlation was observed in the PD-depressed patients.
Additionally, the PD-All group showed a positive correlation
between l-DOPA and the rigidity sub-group score of the UPDRS
scale and this same correlation was present only in PD-non-
depressed patients, which confirmed that this group was driving
the significant results.
It should also be noted that only PD-depressed patients revealed
negative correlation between l-DOPA dosage and neuropsycho-
logical tests of RAVLT-recognition and the Brixton test. This
would suggest that PD-depressed patients drove the negative cor-
relation between the PD-All group and the neuropsychological
tests and indicates that in PD patients with depressive symp-
toms, higher doses of l-DOPA correlate with lower results on
cognitive tests.
DISCUSSION
The present study analyzed the influences of depressive symptoms
on-medication in PD and three major findings were determined:
(A) PD-depressed patients received higher dosages of l-DOPA
medication; (B) in PD-non-depressed patients l-DOPA dosage
had a strong positive correlation with duration of disease, while
in PD-depressed patients, this correlation was absent; (C) only
l-DOPA had a strong positive correlation with depressive symp-
toms in PD-All group, specifically with the cognition and somatic
components of the BDI-II scale.
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L-DOPA AND DEPRESSIVE SYMPTOMS
One explanation of increased l-DOPA dosage administered to
PD-depressed patients is the misdiagnosing of depression in PD
patients, as it has been reported (13, 14). This could be due to
specific differences between depression in PD and depression as
a primary affective disorder (17–19, 68) but can also be due to
often observed somatic symptoms of depression in PD patients
without depression (20). Furthermore, multiple studies reported
that depression in PD presents fewer dysphoric symptoms such
as guilt and suicidal ideation and more somatic and cognitive
symptoms, which additionally can be confused with Parkinsonism
manifestations (17–19, 69, 70). Considering the above similari-
ties and differences, some of the depressive symptoms might have
been confused with PD aggravation and might have motivated the
increase of l-DOPA dosages.
Strikingly, our results showed a positive correlation in the group
of all PD patients only between l-DOPA and the BDI-II scale
somatic and cognitive components. Previous studies also reported
that depression in PD presents more somatic and cognitive symp-
toms (17–19, 69, 70). Nevertheless, this positive correlation reveals
either that (1) an increase of l-DOPA dosage could worsen the
depressive symptoms, or (2) due to impairment of BDI-II compo-
nents, the dosages of l-DOPA have been increased. Considering
that PD-depressed patients were administered significantly higher
dosages of l-DOPA and these dosages did not correlate with dura-
tion of disease nor with UPDRS score in PD-depressed, it is more
likely the first case scenario.
Increased l-DOPA dosage in PD-depressed and the strong
influence of l-DOPA on depressive symptoms can be explained
by the differential dopaminergic depletion of ventral and dorsal
striatum in PD (42, 43). It has been shown that in the initial phase
of PD, the dopamine in the dorsal striatum is severely depleted,
while the ventral striatum is relatively intact. Thus, the dopamine
treatment in this phase will improve the dorsal striatum functions
(the motor symptoms), while the l-DOPA overdose in the ventral
striatum will determine a dysregulation of functions, inducing
depressive symptoms. Interestingly, the deep brain stimulation of
nucleus accumbens (ventral striatum) has been shown to decrease
depression in treatment-resistant depression (71).
Additionally, the dopamine overdose effect in the ventral stria-
tum has been linked with cognition impairment in PD patients
in our previous study (43) and, our present study also revealed
some results with respect to cognition. The ANOVA analyses
showed a difference between the two PD groups on the RAVLT
tests and the correlation analysis showed a negative correlation
between l-DOPA dosage and the cognitive neuropsychological
tests of RAVLT. Extensive studies in rodents showed that nucleus
accumbens receives afferent projections from the prefrontal cor-
tex (72–74) and it is believed that dopamine influences nucleus
accumbens activation by prefrontal cortex afferents (75–77). From
this point of view, the treatment induced dopamine overdose in the
ventral striatum can have an influence on cognitive function asso-
ciated with the prefrontal cortex. Some studies also reported that
antiparkinsonian medication might be associated with cognitive
impairment (78–80).
It has been reported that the prefrontal cortex, nucleus accum-
bens, and basolateral amygdala are the main targets of the
meso-cortical and meso-limbic dopamine systems and represent
core structures at the interfaces of addiction (81). Several stud-
ies demonstrated that rhythmic interactions between prefrontal
cortex, nucleus accumbens, and basolateral amygdala are central
to cognitive functions such as learning and memory (82–84).
These regions are the site of severe functional adaptations and
homeostatic impairments following chronic drug exposure (85–
87). Interestingly, patients with DDS exhibit enhanced l-DOPA-
induced ventral striatum dopamine release (41), and DDS has
been associated with depressive symptoms (39). Thus, the exces-
sive medication usage in PD patients might be determined initially
by the presence of depressive symptoms due to ventral striatum
dysfunction and further PD patients develop addiction-like behav-
ior and abuse the l-DOPA in order to stimulate an excessive
dopamine release.
In our study, the dopaminergic agonists did not show any spe-
cific impact on depressive symptoms or cognitive tests in any of
the groups and there was no difference between the groups with
respect to agonists’ dosage. This would indicate that agonists have
no relationship with depression. An additional support for this
view is that agonists have been reported to be more responsible for
disorders of impulse control, hallucinations, and compulsions (88,
89) while l-DOPA is more linked to anxiety and depression (25).
Taken together, the results argue for the use of non-dopaminergic
approaches for the treatment of depressive symptoms in PD, such
as the use of selective serotonin reuptake inhibitors (90–92).
L-DOPA AND MOTOR FUNCTION
The present study also revealed a positive correlation between
l-DOPA and the UPDRS scores in all PD patients. This would
mean that increased UPDRS scores correlated with increased l-
DOPA dosage. Further, only PD-non-depressed patients showed
a statistically significant positive correlation between the rigidity
sub-group of the UPDRS scale and the l-DOPA dosage, while
the same results for the PD-depressed group were not statis-
tically significant. This would imply that in PD-non-depressed
patients, l-DOPA dosages were administered based on the wors-
ening of the UPDRS score, while in PD-depressed the treatment
was adjusted based on other considerations, possibly including
the presence of depressive symptoms. On the other hand, previ-
ously it has been reported a significant positive correlation between
depression and UPDRS motor scores, including tremor and aki-
nesia (93). Additionally, depression has been shown to impair
even more the motor symptoms in PD (94). Our study showed
the absence of statistically significant differences between the two
PD groups with respect to the UPDRS score. Thus, the possi-
bility that l-DOPA was administered in PD-depressed patients
based on non-motor considerations is to be considered, yet it is
also possible that stronger complaints from patients about the
motor symptoms might also be an argument for increasing the
l-DOPA dosage.
LIMITATIONS
The present study has several limitations. First, we used the
median of the BDI-II score as a limit between the two PD groups
(PD-depressed and PD-non-depressed) and the results might be
biased. However, BDI-II scale is not a diagnostic tool and thus
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reveals only the presence of depressive symptoms and it is often
used and has been validated in PD population. In our study,
its utility was confirmed by the significant statistical difference
between the depressed and non-depressed groups with respect to
l-DOPA dosage and cognitive performance on several neuropsy-
chological tests. Second, our groups have a relatively low number
of subjects. Third, the interaction between l-DOPA and dopamine
agonists has not been ruled out and the effect of combination
of both drugs on depressive symptoms has not been accounted.
Fourth, one cannot conclude necessarily that dopamine over-
dosage in the ventral striatum induces functional impairment in
the prefrontal cortex and, respectively, cognitive impairment only
due to connectivity relationship between the two areas. Never-
theless, this study is strongly confirming the data from previous
reports, and brings additional emphasize on l-DOPA influence.
More research is needed to confirm the direction of the correlation
between higher l-DOPA dosage and depressive symptoms.
CONCLUSION
In conclusion, the results of this study show that in PD patients,
higher l-DOPA dosages correlate with worse depressive symp-
toms and possibly with decreased results in some cognitive per-
formances. From this point of view, PD patients need to be
better diagnosed with respect to depressive symptoms and need
additional treatment adjustment when clinical manifestations of
depression are present. This might be performed by reducing the
l-DOPA dosage or by receiving treatment specific for depressive
symptoms (such as selective serotonin reuptake inhibitors). Clini-
cians must be aware that dopaminergic drugs are not sufficient to
alleviate depressive symptoms. Further longitudinal investigation
is needed to confirm the present hypothesis.
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